英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
annonciation查看　annonciation　在百度字典中的解释百度英翻中〔查看〕
annonciation查看　annonciation　在Google字典中的解释Google英翻中〔查看〕
annonciation查看　annonciation　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Clinical Pharmacology of Antibody-Drug Conjugates - PMC
    Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate
  • Therapeutic ADCs: mechanisms of action and advantages
    The therapeutic value of antibody-drug conjugates (ADCs) is widely recognized as highly effective and safe for the treatment of cancer Internalization and cellular trafficking are two properties that greatly impact their therapeutic value and modulate their mechanism of action
  • Discussing ADC Risks, Benefits, and Regimens With Patients - Pharmacy Times
    Panelists discuss how health care professionals use clear, tailored communication to explain antibody-drug conjugate (ADC) risks, benefits, and regimens They provide education, address concerns, and ensure adherence through counseling and shared decision-making Beginning of dialog window Escape will cancel and close the window
  • What are Antibody Drug Conjugates? The ABCs of ADCs | AbbVie CMO
    Antibody drug conjugates (ADC) are a class of therapeutic agents that combine an active pharmaceutical ingredient (API) with a monoclonal antibody to provide a targeted delivery of the API AbbVie has several ADCs in our pipeline and one commercial product gained with the acquisition of Immunogen
  • Antibody-Drug Conjugates: Patient and Treatment Selection
    Optimizing thresholds of target antigen expression that demonstrate clinical therapeutic benefit will improve applicability of ADCs in the clinical area and improve patient selection
  • Advanced Drug Modalities Part 3: Antibody-Drug Conjugates (ADCs)
    Antibody Drug Conjugates (ADCs) are an innovative targeted cancer therapy, blending precision medicine with cytotoxic chemotherapy efficiency This advanced drug modality offers unique advantages over established modalities such as small molecule drugs and monoclonal antibodies (mAbs), and employs multiple mechanisms of action to treat cancer
  • Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical . . .
    Antibody–drug conjugates (ADCs) are an innovative family of agents assembled through linking cytotoxic drugs (payloads) covalently to monoclonal antibodies (mAbs) to be delivered to tumor tissue that express their particular antigen, with the theoretical advantage of an augmented therapeutic ratio
  • The Journey of Antibody-Drug Conjugates: Lessons Learned from . . . - PubMed
    Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials
  • Frontiers | Advanced therapy to cure diabetes: mission impossible is . . .
    These β-like cells have been responsive to some of the anti-diabetic pharmaceuticals that are known to accelerate insulin production (Bourgeois et al , 2021), and suggests that stem cell-induced-β-like cells from T1D patients can be used not only for the treatment of diabetes but also for personalized drug screening and studies around drug
  • Antibody-drug conjugates (ADCs) fact sheet – Bristol Myers Squibb
    Antibody-drug conjugates (ADCs) are just one promising option in Bristol Myers Squibb’s toolbox of modalities being studied across cancer types Learn more about precision-based therapies for potential cancer treatment
  • Summary and Future Directions of Antibody-Drug Conjugates
    Antibody-drug conjugates (ADCs) have become a powerful class of therapeutics in oncology Since the first approval of Mylotarg ® (gemtuzumab ozogamicin) by the US Food and Drug Administration (FDA) in 2000, the field has grown rapidly with 11 current FDA-approved ADCs
  • Antibody drug conjugate: the “biological missile” for targeted cancer . . .
    It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the
  • ADCs: The next generation of targeted therapies - Drug Discovery World . . .
    Getting new targets for ADCs is a high priority as it could lead to therapies that are more likely to hit cancer cells, allowing for higher doses and greater efficacy with fewer trade-offs needed to ensure an acceptable safety profile
  • Rise of Antibody-Drug Conjugates: The Present and Future
    Enfortumab vedotin (EV) is an ADC with proven survival benefits in the treatment of UCs 43 EV consists of a fully human mAb specific for nectin-4, a cell adhesion molecule, and monomethyl auristatin E (MMAE), an agent that disrupts microtubule formation 44 EV received accelerated FDA approval in 2019 and regular approval in July 2021, after
  • Antibody-Drug Conjugates (ADCs) - Cleveland Clinic
    Antibody-drug-conjugates (ADCs) combine chemotherapy and targeted therapy to treat certain blood cancers and cancerous tumors Oncologists (cancer specialists) may use an ADC when cancers come back (recur), other treatments aren’t effective (refractory cancer) or cancers spread (metastasize)





中文字典-英文字典  2005-2009